A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine|DRUG: Capecitabine/eribulin/gemcitabine/vinorelbine
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.